Asia Pacific Neisseriaceae Infections Market By Type Of Bacteria (N. Meningitidis, N. Gonorrhoeae, N. Sicca N. Flava, N. Elongata, N. Cinerea, Others), By Disease (Gonorrhea, Septicemia, Meningitis, Sinusitis, Otitis, Pneumonia, CNS, Urinary, Respiratory Infections), By Antibacterial Drugs (B-lactum Antibiotics (Penicillin), Clavulanic Acid (Augmentin), Aminoglycosides (Streptomycin), Glycopeptides (Vancomycin), Polypeptides (Bacitracin), Rifamycins (Rifampicin), Chloramphenicol Tetracycline, Others), By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2016–2021)

Asia Pacific Neisseriaceae Infections Market By Type Of Bacteria (N. Meningitidis, N. Gonorrhoeae, N. Sicca N. Flava, N. Elongata, N. Cinerea, Others), By Disease (Gonorrhea, Septicemia, Meningitis, Sinusitis, Otitis, Pneumonia, CNS, Urinary, Respiratory Infections), By Antibacterial Drugs (B-lactum Antibiotics (Penicillin), Clavulanic Acid (Augmentin), Aminoglycosides (Streptomycin), Glycopeptides (Vancomycin), Polypeptides (Bacitracin), Rifamycins (Rifampicin), Chloramphenicol Tetracycline, Others), By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2016–2021)

ID: 4508 | Pages: 139 | November 2017 | Region: Asia Pacific


Asia Pacific Neisseriaceae Infections market size was around USD XX billion in 2016. It is expected to grow at a CAGR of XX% to reach USD XX billion by 2021. Bacteria represent the essential class of micro-organisms that play a crucial role in the development of infection of any disease to human being and animal. They are classified into two types on the basis of gram staining test, viz., gram-positive bacteria and gram-negative bacteria. Neisseria is one of the most important class of bacteria which forms colonies on mucosal surfaces of animals. Neisseria comprises 11 species, out of which, two are pathogenic and others are harmless. These belong to gram negative class of bacteria, because these species show negative response to gram test.

As per the U.S. Centers for Disease Control and Prevention (CDC), more than 300,000 new cases of gonorrhea were reported in the U.S. in 2012, an enhancement of around 4% in contrast to 2011. Therefore, such rising prevalence of infections is an important growth driver of the market. Further, due to extensive R&D practices, number of drugs and formulations are on the way to enter in the market during the forecast period. Some of the important pipeline products include AXD0914, Cribrostatin-6, SM-295291 and SM-369926 amongst numerous others. In addition, owing to rising incidences of homosexuality and bisexuality, the threat of gonorrhea has also increased. These factors are aided by rising awareness regarding the infections and diseases and rising medical expenditure. Due to these, the market is anticipated to grow at steady rate.On the other hand, factors such as government austerity, high cost of treatment and R&D, and ignorance towards the symptoms may hamper the growth of the market to certain extent.

Asia Pacific Neisseriaceae Infections market segmentation by various bacteria that belongs to the class and diseases associated with them, such as, Acinetobacter, Kingella, Neisseria, Moraxella and Oligella. Neisseria contains bacteria such as N. meningitidis, N. gonorrhoeae, N. sicca, N. flava, N. elongata, N. cinerea and others. Out of which, N. gonorrhoeae causes gonorrhea and N. meningitidis causes septicemia and meningitis. Moraxella catarrhalis causes otitis, sinusitis, and pneumonia in adults. Kingella kingae causes urinary, CNS, and respiratory infections. Furthermore, it is classified on the basis of antibacterial drugs, like, aminoglycosides (Streptomycin), B-lactum antibiotics (Penicillin), clavulanic acid (Augmentin), glycopeptides (Vancomycin), polypeptides (Bacitracin), rifamycins (Rifampicin), chloramphenicol, tetracycline and many others.

Neisseriaceae Infections market geographical segmentation by India, China, Korea, Japan and others. Asia-Pacific region is anticipated to show robust growth in the forecast period, due to rapidly growing prevalence and awareness about the diseases caused because of Neisseriaceae and their chronic effects.

Some of the major Neisseriaceae Infections market leaders are Aphios Corporation, Basilea Pharmaceuticals Ltd., Pfizer, Inc., GSK plc, AstraZeneca plc, Adenium Biotech ApS, Dainippon Sumitomo Pharma Co., Ltd., Theravance, Inc., and Pfizer, Inc. amongst many others.

1. Introduction                                                                 

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                               

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                       

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 Epidemology                                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                    

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

5. Market Segmentation                                                                              

                5.1 Type Of Bacteria                                                       

                                5.1.1 Introduction                                           

                                5.1.2 N. Meningitidis                                      

                                5.1.3 N. Gonorrhoeae                                   

                                5.1.4 N. Sicca                                     

                                5.1.5 N. Flava                                    

                                5.1.6 N. Elongata                                             

                                5.1.7 N. Cinerea                                               

                                5.1.8 Others                                      

                                5.1.9  Y-o-Y Growth Analysis, By Type Of Bacteria                                             

                                5.1.10  Market Attractiveness Analysis, By Type Of Bacteria                                         

                                5.1.11  Market Share Analysis, By Type Of Bacteria                                          

                5.2 Disease                                                        

                                5.2.1 Introduction                                           

                                5.2.2 Gonorrhea                                              

                                5.2.3 Septicemia                                              

                                5.2.4 Meningitis                                               

                                5.2.5 Sinusitis                                    

                                5.2.6 Otitis                                          

                                5.2.7 Pneumonia                                             

                                5.2.8 CNS                                            

                                5.2.9 Urinary                                     

                                5.2.10 Respiratory Infections                                     

                                5.2.11 Y-o-Y Growth Analysis, By Disease                                             

                                5.2.12 Market Attractiveness Analysis, By Disease                                           

                                5.2.13 Market Share Analysis, By Disease                                             

                5.3 Antibacterial Drugs                                                  

                                5.3.1 Introduction                                           

                                5.3.2 B-lactum Antibiotics (Penicillin)                                      

                                5.3.3 Clavulanic Acid (Augmentin)                                            

                                5.3.4 Aminoglycosides (Streptomycin)                                   

                                5.3.5 Glycopeptides (Vancomycin)                                          

                                5.3.6 Polypeptides (Bacitracin)                                  

                                5.3.7 Rifamycins (Rifampicin)                                     

                                5.3.8 Chloramphenicol                                  

                                5.3.9 Tetracycline                                            

                                5.3.10 Others                                    

                                5.3.11 Y-o-Y Growth Analysis, By Antibacterial Drugs                                       

                                5.3.12  Market Attractiveness Analysis, By Antibacterial Drugs                                    

                                5.3.13  Market Share Analysis, By Antibacterial Drugs                                     

6. Geographical Analysis                                                                              

                6.1 Introduction                                                               

                                6.1.1 Regional Trends                                    

                                6.1.2 Impact Analysis                                     

                                6.1.3 Y-o-Y Growth Analysis                                        

                                                6.1.3.1 By Geographical Area                     

                                                6.1.3.2 By Type Of Bacteria                         

                                                6.1.3.3 By Disease                           

                                                6.1.3.4 By Antibacterial Drugs                    

                                6.1.4  Market Attractiveness Analysis                                     

                                                6.1.4.1 By Geographical Area                     

                                                6.1.4.2 By Type Of Bacteria                         

                                                6.1.4.3 By Disease                           

                                                6.1.4.4 By Antibacterial Drugs                    

                                6.1.5  Market Share Analysis                                      

                                                6.1.5.1 By Geographical Area                     

                                                6.1.5.2 By Type Of Bacteria                         

                                                6.1.5.3 By Disease                           

                                                6.1.5.4 By Antibacterial Drugs                    

                6.2 China                                                             

                6.3 India                                                              

                6.4 Japan                                                            

                6.5 South Korea                                                               

                6.6 Australia                                                      

7. Strategic Analysis                                                                       

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

8. Market Leaders' Analysis                                                                        

                8.1 Basilea Pharmaceuticals Ltd.                                               

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Financial analysis                                  

                                8.1.4 Recent Developments                                       

                                8.1.5 SWOT analysis                                       

                                8.1.6 Analyst View                                          

                8.2 AstraZeneca plc                                                        

                8.3 Adenium Biotech ApS                                                            

                8.4 Dainippon Sumitomo Pharma Co. Ltd.                                                            

                8.5 Aphios Corporation                                                 

                8.6 Pfizer Inc.                                                    

                8.7 GSK plc                                                         

                8.8 Theravance Inc.                                                        

9. Competitive Landscape                                                                           

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

10. Market Outlook and Investment Opportunities                                                                         

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of type, Disease, Antibacterial Drugs along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the Asia Pacific Market; which includes broadly demographic, economic and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia Pacific Neisseriaceae Infections Market By Type Of Bacteria, From 2016-2021 ( USD Million )
  2. Asia Pacific N. Meningitidis Market By Region, From 2016-2021 ( USD Million )
  3. Asia Pacific N. Gonorrhoeae Market By Region, From 2016-2021 ( USD Million )
  4. Asia Pacific N. Sicca Market By Region, From 2016-2021 ( USD Million )
  5. Asia Pacific N. Flava Market By Region, From 2016-2021 ( USD Million )
  6. Asia Pacific N. Elongata Market By Region, From 2016-2021 ( USD Million )
  7. Asia Pacific N. Cinerea Market By Region, From 2016-2021 ( USD Million )
  8. Asia Pacific Others Market By Region, From 2016-2021 ( USD Million )
  9. Asia Pacific Neisseriaceae Infections Market By Disease, From 2016-2021 ( USD Million )
  10. Asia Pacific Gonorrhea Market By Region, From 2016-2021 ( USD Million )
  11. Asia Pacific Septicemia Market By Region, From 2016-2021 ( USD Million )
  12. Asia Pacific Meningitis Market By Region, From 2016-2021 ( USD Million )
  13. Asia Pacific Sinusitis Market By Region, From 2016-2021 ( USD Million )
  14. Asia Pacific Otitis Market By Region, From 2016-2021 ( USD Million )
  15. Asia Pacific Pneumonia Market By Region, From 2016-2021 ( USD Million )
  16. Asia Pacific CNS Market By Region, From 2016-2021 ( USD Million )
  17. Asia Pacific Urinary Market By Region, From 2016-2021 ( USD Million )
  18. Asia Pacific Respiratory Infections Market By Region, From 2016-2021 ( USD Million )
  19. Asia Pacific Neisseriaceae Infections Market By Antibacterial Drugs, From 2016-2021 ( USD Million )
  20. Asia Pacific B-lactum Antibiotics (Penicillin) Market By Region, From 2016-2021 ( USD Million )
  21. Asia Pacific Clavulanic Acid (Augmentin) Market By Region, From 2016-2021 ( USD Million )
  22. Asia Pacific Aminoglycosides (Streptomycin) Market By Region, From 2016-2021 ( USD Million )
  23. Asia Pacific Glycopeptides (Vancomycin) Market By Region, From 2016-2021 ( USD Million )
  24. Asia Pacific Polypeptides (Bacitracin) Market By Region, From 2016-2021 ( USD Million )
  25. Asia Pacific Rifamycins (Rifampicin) Market By Region, From 2016-2021 ( USD Million )
  26. Asia Pacific chloramphenicol, Market By Region, From 2016-2021 ( USD Million )
  27. Asia Pacific tetracycline Market By Region, From 2016-2021 ( USD Million )
  28. Asia Pacific Others Market By Region, From 2016-2021 ( USD Million )
  29. Japan Neisseriaceae Infections Market By Type Of Bacteria, From 2016-2021 ( USD Million )
  30. Japan Neisseriaceae Infections Market By Disease, From 2016-2021 ( USD Million )
  31. Japan Neisseriaceae Infections Market By Antibacterial Drugs, From 2016-2021 ( USD Million )
  32. China Neisseriaceae Infections Market By Type Of Bacteria, From 2016-2021 ( USD Million )
  33. China Neisseriaceae Infections Market By Disease, From 2016-2021 ( USD Million )
  34. China Neisseriaceae Infections Market By Antibacterial Drugs, From 2016-2021 ( USD Million )
  35. India Neisseriaceae Infections Market By Type Of Bacteria, From 2016-2021 ( USD Million )
  36. India Neisseriaceae Infections Market By Disease, From 2016-2021 ( USD Million )
  37. India Neisseriaceae Infections Market By Antibacterial Drugs, From 2016-2021 ( USD Million )
  38. Australia Neisseriaceae Infections Market By Type Of Bacteria, From 2016-2021 ( USD Million )
  39. Australia Neisseriaceae Infections Market By Disease, From 2016-2021 ( USD Million )
  40. Australia Neisseriaceae Infections Market By Antibacterial Drugs, From 2016-2021 ( USD Million )
  41. South Korea Neisseriaceae Infections Market By Type Of Bacteria, From 2016-2021 ( USD Million )
  42. South Korea Neisseriaceae Infections Market By Disease, From 2016-2021 ( USD Million )
  43. South Korea Neisseriaceae Infections Market By Antibacterial Drugs, From 2016-2021 ( USD Million )
Middle-East And Africa Antibody Drug Conjugates Market By Pipeline Analysis (Phase, Mode Of Action [IgG1 Antibodies, HER2 Antibodies], Technology [Seattle Genetics, Immunogen, Immunomedics], Linker), End-user (Resea...
Latin America Antibody Drug Conjugates Market By Pipeline Analysis (Phase, Mode Of Action [IgG1 Antibodies, HER2 Antibodies], Technology [Seattle Genetics, Immunogen, Immunomedics], Linker), End-user (Research Insti...
Asia-Pacific Antibody Drug Conjugates Market By Pipeline Analysis (Phase, Mode Of Action [IgG1 Antibodies, HER2 Antibodies], Technology [Seattle Genetics, Immunogen, Immunomedics], Linker), End-user (Research Instit...
Europe Antibody Drug Conjugates Market By Pipeline Analysis (Phase, Mode Of Action [IgG1 Antibodies, HER2 Antibodies], Technology [Seattle Genetics, Immunogen, Immunomedics], Linker), End-user (Research Institutes, ...
North America Antibody Drug Conjugates Market By Pipeline Analysis (Phase, Mode Of Action [IgG1 Antibodies, HER2 Antibodies], Technology [Seattle Genetics, Immunogen, Immunomedics], Linker), End-user (Research Insti...
ANtibody Drug Conjugates Market By Pipeline Analysis (Phase, Mode Of Action [IgG1 Antibodies, HER2 Antibodies], Technology [Seattle Genetics, Immunogen, Immunomedics], Linker), End-user (Research Institutes, Hospita...
Middle-East And Africa Early Toxicity Testing Market By Technique (In-vitro, In-vivo And In-Silico), Assays (Cell-Based ELISA And Western Blots, Enzyme Toxicity Assays, Receptor Binding Assays, Bacterial Toxicity As...
Latin America Early Toxicity Testing Market By Technique (In-vitro, In-vivo And In-Silico), Assays (Cell-Based ELISA And Western Blots, Enzyme Toxicity Assays, Receptor Binding Assays, Bacterial Toxicity Assays, Tis...
Asia-Pacific Early Toxicity Testing Market By Technique (In-vitro, In-vivo And In-Silico), Assays (Cell-Based ELISA And Western Blots, Enzyme Toxicity Assays, Receptor Binding Assays, Bacterial Toxicity Assays, Tiss...
Europe Early Toxicity Testing Market By Technique (In-vitro, In-vivo And In-Silico), Assays (Cell-Based ELISA And Western Blots, Enzyme Toxicity Assays, Receptor Binding Assays, Bacterial Toxicity Assays, Tissues Cu...
North America Early Toxicity Testing Market By Technique (In-vitro, In-vivo And In-Silico), Assays (Cell-Based ELISA And Western Blots, Enzyme Toxicity Assays, Receptor Binding Assays, Bacterial Toxicity Assays, Tis...
Early Toxicity Testing Market By Technique (In-vitro, In-vivo And In-Silico), Assays (Cell-Based ELISA And Western Blots, Enzyme Toxicity Assays, Receptor Binding Assays, Bacterial Toxicity Assays, Tissues Culture A...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.